Statistical analysis of the primary pharmacokinetic parameters

	Geometric mean
Parameter	Impaired	Normal renal function	Comparison (Group names)	Ratio of means (impaired: normal function)	90% confidence interval
AUC(0,∞) (ng ml−1 mg−1 m−2); per unit of dose)*
Topotecan lactone	6.33	5.90	B: A	1.07	(0.70−1.64)
Total topotecan	24.30	21.55	B: A	1.13	(0.78−1.64)
Topotecan lactone	8.03	5.90	C: A	1.36	(0.92−2.02)
Total topotecan	34.77	21.55	C: A	1.61	(1.14−2.28)
Topotecan lactone	12.33	5.90	D: A	2.09	(1.38−3.16)
Total topotecan	53.37	21.55	D: A	2.48	(1.72−3.56)
Topotecan lactone	16.13	5.90	E: A	2.74	(1.72−4.36)
Total topotecan	85.86	21.55	E: A	3.98	(2.64−6.01)
Cmax (ng ml−1 mg−1 m−2; per unit of dose)*
Topotecan lactone	1.56	1.59	B: A	0.98	(0.63−1.53)
Total topotecan	3.54	2.99	B: A	1.18	(0.82−1.70)
Topotecan lactone	1.91	1.59	C: A	1.20	(0.79−1.81)
Total topotecan	4.83	2.99	C: A	1.61	(1.15−2.26)
Topotecan lactone	2.23	1.59	D: A	1.41	(0.91−2.17)
Total topotecan	5.34	2.99	D: A	1.79	(1.25−2.55)
Topotecan lactone	2.46	1.59	E: A	1.55	(0.95−2.53)
Total topotecan	7.06	2.99	E: A	2.36	(1.58−3.53)

^*Doses are normalized to 1 mg m⁻² day⁻¹. Abbreviations: AUC(0,∞), Area under the concentration-time curve from zero (pre-dose) extrapolated to infinity; C_max, maximum observed plasma concentration.